AllDocs -> cancers

782 | OCTOBER 2004 | VOLUME 5 www.nature.com/reviews/neuro R E V I E W S In Anna Karenina ,Leo Tolstoy wrote:‘All happy families resemble one another,each unhappy family is unhappy in its own way’.Oddly enough,this might be a rather apt analogyfor cancer .The highly regulated molecular events that are crucial for normal development and function are very similar between individuals,but in cancer ,genetic and epigenetic alterations result in cascades of deregu- lated molecular events,which lead to genetically com- plex, highly individual tumours. The complexity is daunting,but finding consistencies that can be therapeu- tically exploited is vital for the development and clinical application of new treatments.Until recently,the tools that are required to attack this problem were not avail- able,but the sequencing of the human genome and the development ...

INFORMATION ON THE BRAIN AND BRAIN CANCER Tumors of the Brain Cancerous tumors are groups of cells in the body that start to grow abnormally. As these cells grow and divide, they begin to crowd or replace normal tissue. Cells become cancerous when their DNA, which is essentially their directions for operation, is damaged and the body fails to either destroy the cells or repair the DNA. There are many ways that DNA can be damaged. Sometimes people inherit damaged DNA, and many times a person’s DNA is damaged through exposure to environmental factors that can damage DNA, such as smoking, pollution, or radiation. There are many types of cancer . The effects and development of a tumor have a lot to do with where in the body it appears and as a result affects the kinds of treatments that can be used. This is why doctors choose treatments that are specifically targeted for a certain type of cancer ...

Bellarminestudent, fan - Willem Knapen September 22, 1988 - August 3, 2005 would be able to donate his brain for research - with the hope that he would be able to contribute to finding a cure for brain cancer . JW will be missed by his Bellarmine Community and by the friends and family he leaves behind - but his legacy will live on through the JW House, a "home away from home" for families of patients at Kaiser, Santa Clara and the help he'll provide for others who will need support as they fight illness in the future. We salute you, JW - truly a Bellarmine "Man for Others." On Wednesday, August 3rd, Jan-Willem Knapen passed away peacefully, surrounded ...

Revolutionizing the treatment of brain cancer and other disorders Radiation equipment designed in Solid Edge offers a non-invasive alternative to surgery www.ugs.com Medical devices A mission to improve care Elekta is an international medical technology group providing clinical solutions, comprehensive information systems and services for improved cancer care and management of brain disorders. All of Elekta’s solutions employ non-invasive or minimally invasive techniques and are clinically effective, gentle on the patient and cost-effective. Elekta’s systems and solutions are used at more than 3,000 hospitals around the world to treat cancer and manage clinical operations as well as to diagnose and treat brain disorders, including tumors, vascular malformations and functional disorders. “When you are on the cutting ...

Translational Research Working Group Preparing for or a Revolution: NCI’s Efforts in Translational Research Anna D. Barker, Ph.D. Deputy Director National Cancer Institute Page 2 National Cancer Act of 1971 “Make the Conquest of Cancer a National Crusade” President Richard Nixon signs National Cancer Act on December 23, 1971 The Beginning! Page 3 A National and International Imperative to Eliminate the Cancer Burden A National and International Imperative to Eliminate the Cancer Burden Canada 138,000 / 66,000 United States of America 1.4M / 566,000 Australia 86,000 / 37,000 China 2.2M / 1.6M Austria 37,000 / 19,000 France ...

1 Deepak Kamnasaran, PhD Divisions of Pediatric Neuro-oncology and Neurosurgery Hospital for Sick Children & Toronto Western Hospital dkamnasa@sickkids.ca CURRENT GENOMIC AND PROTEOMIC APPROACHES TO ELUCIDATE NOVEL CAUSES OF BRAIN CANCER HISTORICAL PERSPECTIVES ON BRAIN TUMORS Neolithic - trephination 1800’s – Dr. Hughes Bennett 1900’s Dr. Harvey Cushing Page 2 2 EPIDEMIOLOGY OF BRAIN TUMORS Primary brain tumors account for 1 in 5 autopsy cases of cancer related deaths - 7% of deaths before the age of 70 - 15% of deaths before the age of 15 Secondary/metastatic brain tumors account for 100,000 new cases per yr Primary & Secondary Percentage of Benign Percentage of Benign vs vs Malignant brain tumor patients Malignant brain tumor patients ...

The GSM Association (GSMA) is the global trade association that exists to promote, protect and enhance the interests of GSM mobile operators throughout the world. www.gsmworld.com The MMF is an international association of wireless communications manufacturers established to support scientific research in relation to mobile telephony and health www.mmfai.info INTERPHONE: Mobile phone brain cancer study in Germany Adding to a growing list of completed national INTERPHONE projects, medical researchers in Germany have published their epidemiological study on the association of mobile and cordless phone use with two types of brain cancer , glioma * and meningioma † . The researchers were mostly medical statisticians and epidemiologists from various research bodies in Germany and were led by Dr Joachim Schüz. The study was funded by contributions from the ...

The GSM Association (GSMA) is the global trade association that exists to promote, protect and enhance the interests of GSM mobile operators throughout the world. www.gsmworld.com The MMF is an international association of wireless communications manufacturers established to support scientific research in relation to mobile telephony and health www.mmfai.info INTERPHONE: Mobile phone brain cancer study in the UK As part of the INTERPHONE project, UK medical researchers have published a large epidemiological study on the association between mobile phone use and the brain cancer , glioma * . The researchers were mostly medical statisticians and epidemiologists from various Centres and Institutes in England. The study was published on line in the British Medical Journal in January 2006. Study Design The study used a population based case-control design. The cases consisted ...

Cannabis may block growth of brain cancer By James Hamilton Cannabis chemicals may provide a new way of treating deadly brain cancer . Scientists have shown that cannabinoids – the chemicals responsible for the drug’s “high” – deter the growth of blood vessels which feed the tumour. They appear to prevent genes making a protein called VEGF (vascular endothelial growth factor) that stimulates the sprouting of blood vessels. Cutting off tumours’ blood supply is one of the latest anti- cancer strategies being explored by scientists. In studies cannabinoids significantly reduced the activity of VEGF in laboratory mice. They also lowered VEGF levels in tumour tissue samples taken from two patients with glioblastoma multiforme, the most lethal brain tumour type. About 4400 new cases of brain tumour are diagnosed in the UK each year. A small percentage of these are grade four gliomas, the most aggressive ...

Brain Cancer What is the Brain? The brain is a soft, spongy mass of tissue that is protected by the bones of the skull and three thin membranes called meninges. Watery fluid called cerebrospinal fluid cushions the brain. A network of nerves carries messages back and forth between the brain and the rest of the body. There are three major parts of the brain: (1) cerebrum, (2) cerebellum, and (3) brain stem. What is Brain Cancer? Brain tumors can be either benign or malignant. Benign tumors do not contain cancer cells and rarely become malignant. Malignant brain tumors are generally more serious and often are life threatening, grow rapidly and very rarely, break away from a malignant brain tumor and spread to other parts of the brain, spinal cord or body. Tumors that begin in brain tissue are known as primary tumors. ...

1 Center for Environmental Health, Community Assessment Program Evaluation of Brain Cancer Incidence in Weston and Wayland, MA January 2006 Massachusetts Department Of Public Health Page 2 Appendix A: Coding Definitions of Cancer Site/Type* Table of Contents I. Introduction 1 II. Methods. 1 III. Results 3 A. Brain Cancer Incidence in Weston 4 B. Brain Cancer Incidence in Wayland.5 C. Temporal Distribution of Brain Cancer in Weston and Wayland .6 D. Geographic Distribution of Brain Cancer .7 E. Review of Case Information ..7 IV. Discussion and Conclusions .. 10 V. Recommendations 12 VI. References. 13 Tables and Figures Table 1. ...

No Sex Age Key word Histological Dianosis Grade 1 A 1,2 m 32 glioblastoma 1. Brain , parietal lobe, right, curettage: glioblastoma with meningeal involvement 2. Dura, excision: extension of glioblastoma. ? 2 A 3,4 m 61 glioblastoma Brain mass, right posterooccipital, removal: 1) recurrent glioblastoma 2) radionecrosis of cortex and white matter. ? 3 A 5,6 m 31 glioblastoma Brain , 3rd ventricle, removal: glioblastoma. ? 4 A 7,8 f 41 anaplastic astrocytoma Brain , tumor removal: anaplastic astrocytoma (WHO grade III) note: neoplastic cells shows moderately pleomorphic nuceli and mitosis. No necrosis and vascular endothelial proliferation is seen. ? 5 A 9,10 f 37 anaplastic astrocytoma Brain , left frontal, removal of tumor: ...

All-Ireland cancer statistics 1994-96 90 Brain 21. MALIGNANT CANCER OF THE BRAIN (summary) ICD-O.2 C71 ICD-10 C71 ICD-9 191 Figures presented are for primary, malignant tumours. Cancer of the meninges (ICD-10 C70) or of the central nervous system (C72) other than the brain itself are excluded, except where comparison is made with EU figures. Key facts • Average of 315 new cases per year, 1994-96: 148 in females, 200 in males. • Average of 297 deaths per year: 130 in females, 167 in males. • Age-standardised incidence and mortality rates about 50% higher in males than females. • 11th most common site for cancer incidence in males, 15th in females. • 8th most common cause of cancer deaths in females, 9th in males. • Median age at diagnosis 57 years for females and 55 years for males (lower than for cancers as a whole). ...

Page 2 Brain cancer in England 1998/9 to 2002/3. A geographical profile of hospital admissions. Authors: Michael Goldacre, David Yeates, Leicester Gill, Henry McGuinness, Daniel Meddings Published by: Unit of Health-Care Epidemiology, Oxford University, and South East England Public Health Observatory, 2005 This document provides a geographical profile of hospital admission for brain cancer in England. The geographical areas covered are the standard local authority areas of England. The period covered is April 1 1998 to March 31 2003. The data are from Hospital Episode Statistics (HES). HES includes data on all NHS hospital admissions (including admissions for day case care). This analysis includes HES data about men and women of all ages. The maps show: (a) The spell-based admission rates per 100,000 resident population for each local authority per year, ...

1672 Main St. Ste. E #264 • Ramona, CA 92065 • Tel: 760.789.8928 • Fax: 760.789.8929 • Toll Free: 800.475.1955 • www.proteinbiotechnologies.com HUMAN BRAIN CANCER TISSUE ARRAY Catalog Number: TMA-138 Each two (2) dots from two different tissue spots represents one single specimen that was selected and pathologically confirmed ( Brain glioblastoma tissue array) Cases: 32 Cores: 63 Diameter: 1.5mm Thickness: 5 µm Standard IHC: GFAP confirmed Layout : 7 x 9 1 2 3 4 5 6 7 8 9 A 1 2 3 4 5 6 7 8 9 B 10 11 12 13 14 15 16 17 18 C 19 20 21 22 23 24 25 26 27 D 28 29 30 31 32 33 34 35 36 ...

1672 Main St. Ste. E #264 • Ramona, CA 92065 • Tel: 760.789.8928 • Fax: 760.789.8929 • Toll Free: 800.475.1955 • www.proteinbiotechnologies.com HUMAN BRAIN CANCER TISSUE ARRAY Catalog Number: TMA-137 Each three (3) dots from three different tissue spots represents one single specimen that was selected and pathologically confirmed ( Brain glioblastoma tissue array) Cases: 21 Cores: 63 Diameter: 1.5mm Thickness: 5 µm Standard IHC: GFAP confirmed Layout : 7 x 9 1 2 3 4 5 6 7 8 9 A 1 2 3 4 5 6 7 8 9 B 10 11 12 13 14 15 16 17 18 C 19 20 21 22 23 24 25 26 27 D 28 29 30 31 32 33 34 35 36 ...

1672 Main St. Ste. E #264 • Ramona, CA 92065 • Tel: 760.789.8928 • Fax: 760.789.8929 • Toll Free: 800.475.1955 • www.proteinbiotechnologies.com HUMAN BRAIN CANCER TISSUE ARRAY Catalog Number: TMA-140 Each two (2) dots from two different tissue spots represents one single specimen that was selected and pathologically confirmed ( Brain glioma tissue array) Cases: 33 Cores: 63 Diameter: 1.5mm Thickness: 5 µm Standard IHC: GFAP confirmed Layout : 7 x 9 1 2 3 4 5 6 7 8 9 A 1 2 3 4 5 6 7 8 9 B 10 11 12 13 14 15 16 17 18 C 19 20 21 22 23 24 25 26 27 D 28 29 30 31 32 33 34 35 36 ...

1672 Main St. Ste. E #264 • Ramona, CA 92065 • Tel: 760.789.8928 • Fax: 760.789.8929 • Toll Free: 800.475.1955 • www.proteinbiotechnologies.com HUMAN BRAIN CANCER TISSUE ARRAY Catalog Number: TMA-139 Each dot represents a DISEASED tissue spot from one individual specimen that was selected and pathologically confirmed ( Brain glioma tissue array) Cases: 62 Cores: 63 Diameter: 1.5mm Thickness: 5 µm Standard IHC: GFAP confirmed Layout : 7 x 9 1 2 3 4 5 6 7 8 9 A 1 2 3 4 5 6 7 8 9 B 10 11 12 13 14 15 16 17 18 C 19 20 21 22 23 24 25 26 27 D 28 29 30 31 32 33 34 35 36 E ...

Vol. 52 - No. 23 June 5, 1998 BROOKHAVEN NATIONAL LABORATORY Director’s Corner N ewsday Series Can Change Misconceptions Mammography and Brain Cancer Treatment — New Approaches Under Development at NSLS Last month, about 350 of the more than 2,400 researchers who use BNL ’s National Synchrotron Light Source ( NSLS ) each year flocked to Brookhaven for the NSLS Annual Users Meeting. Stories about the meeting are planned for next week’s Brookhaven Bulletin. This week, the Bulletin takes a look at the research that two teams of NSLS users are pursuing to help improve some cancer treatment and diagnosis. ‘Dramatic Improvement’ in Breast- Cancer Imaging Tomorrow’s mammo- grams could be much more effective at spotting ex- tremely small ...

24509 N.E. 27 th Place, Sammamish, WA 98074 www.ChrisElliottFund.org Christopher S. Elliott Memorial Glioblastoma Brain Tumor Research Fund is a 501 (c) 3 non-profit organization Tax Exempt # 042-263-040 White Copy (Office), Canary Copy (File), Pink Copy (Donor Tax Receipt) 4 th Annual Christopher S. Elliott Memorial Golf Scramble Benefiting Glioblastoma Brain Cancer Research Bear Creek Country Club ? 13737 202 nd Ave. NE ? Woodinville ? WA Monday, September 12 th , 2005 ? GOLF REGISTRATION FORM ? (Pre-registration required by: August 20, 2005) Team Captain :_HCP Player #2 : HCP _ Address _ Address City, State, Zip _ City, State, Zip __ Email address __ Email address ...

brain cancer 1185 R Tutorial: Connectivity, Group-Conformity, and Significance: Understanding Gene Co-Expression Network Methods. Applied to Brain Cancer Microarray Data Jun Dong, Steve Horvath Correspondence: shorvath@mednet.ucla.edu , http://www.ph.ucla.edu/biostat/people/horvath.htm This R tutorial describes how to carry out a gene co-expression network analysis based on factorizability decomposition with the R software. We show how to perform the factorizability decomposition and calculate important module quantities such as tightness, uniformity, conformities and factorizability. Other quantities include connectivity and clustering coefficients. We investigate their interrelationship. Further, we show how to compute module eigengenes and how to relate them to each other and to external microarray sample traits. This is a self-contained tutorial that assumes ...

Review Stem cells and brain cancer U Galderisi* ,1,2 , M Cipollaro 2 and A Giordano 1 1 Sbarro Institute for Cancer Research and Molecular Medicine, College of Science and Technology, Temple University, Philadelphia, PA, USA 2 Department of Experimental Medicine, Section of Biotechnology and Molecular Biology, Excellence Research Center for Cardiovascular Diseases, Second University of Naples, Naples, Italy * Corresponding author: U Galderisi, Department of Experimental Medicine, Section of Biotechnology and Molecular Biology, Second University of Naples, Via Costantinopoli 16, 80138 Napoli, Italy. Tel: þ39 0815665886; Fax: þ 390815667547; E-mail: umberto.galderisi@unina2.it Received 16.3.05; revised 17.6.05; accepted 01.7.05; published online 26.8.05 Edited by G Cossu Abstract An increasing body of research ...

Brain cancer can be counted among the most deadly and intractable diseases. Often diagnosed after a patient exhibits symptoms such as nausea, dizziness, uncharacteristic behavior changes, or paralysis, the growing mass of a brain tumor will continue to squeeze out normal tissue and degrade the brain's function if left untreated. But treatment is elusive. Tumors may be embedded in regions of the brain that are critical to orchestrating the body's vital functions, while they shed cells to invade other parts of the brain , forming more tumors too small to detect using conventional imaging techniques. Brain cancer's location and ability to spread quickly makes treatment with surgery or radiation like fighting an enemy hiding out among minefields and caves, and explains why the term " brain cancer " is all too often associated with the word "inoperable." ...

K S Biomedix Holdings PLC ( LS:KSB ) Licenses TransMID Brain Cancer Product To Sosei Co., Ltd. In $25 Million Japanese Deal GUILDFORD, England and LONDON and TOKYO, May 27 /PRNewswire-FirstCall/ - - KS Biomedix Holdings plc ("KSB") (LSE: KSB) and Sosei Co. Ltd. ("Sosei") announce that KSB has appointed Sosei as the Japanese licensee for its TransMID(TM) product in a $25 million licensing deal. TransMID(TM) is a novel biopharmaceutical product in development for the treatment of recurrent high grade glioma, a terminal brain cancer for which there is no known cure. This deal is the first TransMID(TM) licensing deal agreed by KSB since it acquired the technology in July 2001. Japan constitutes around 20% of the total worldwide market for glioma treatments and is the second largest single market in the world after the USA. Under the terms of the deal, KSB will receive an upfront payment together with staged ...

Trial shows which brain cancer patients benefit from temozolomide Genetic predictive test clears way for targeted drug treatment An international team of scientists and cancer specialists has identified which patients with the deadly form of brain tumours called glioblastomas are likely to live longer if they are treated with temozolomide, and which patients are likely to get only marginal, if any, benefit. The genetic predictive test on tumour biopsies to identify who will benefit from the drug could be carried out fairly easily in any genetics laboratory and takes only two to three days, although the availability and quality of the tissue is an important issue. If implement widely it would mean that temozolomide would become a targeted treatment. Dr Monika Hegi told the EORTC-NCI-AACR 1 Symposium on Molecular Targets and Cancer Therapeutics in Geneva today that the key to predicting ...

Massachusetts Department Of Public Health Center for Environmental Health, Community Assessment Program Evaluation of Brain and Central Nervous System Cancer Incidence in Arlington, Massachusetts 1982-2001 October 2005 Page 2 i I. INTRODUCTION 1 II. METHODS FOR ANALYZING CANCER INCIDENCE. 2 A. Case Identification/Definition 2 B. Calculation of Standardized Incidence Ratios (SIRs) 3 C. Interpretation of a Standardized Incidence Ratio (SIR) 4 D. Calculation of the 95% Confidence Interval.. 5 E. Evaluation of Cancer Risk Factor Information. 6 F. Determination of Geographic Distribution of Cancer Cases. 6 G. Cancer Incidence in the Reeds Brook Landfill Neighborhood. 7 III. FORMER REEDS BROOK LANDFILL 7 IV. RESULTS OF CANCER INCIDENCE ANALYSIS ...

Census Tract Obs Exp SIR Obs Exp SIR Obs Exp SIR 3561 1 2.0 NC NC -- NC 1 1.0 NC NC -- NC 0 1.0 NC 3562 6 3.5 173 63 -- 377 0 1.5 NC NC -- NC 6 1.9 313 3563 1 3.3 NC NC -- NC 1 1.6 NC NC -- NC 0 1.8 NC 3564 7 5.3 131 53 -- 271 6 2.7 225 82 -- 490 1 2.7 NC 3565 6 4.6 131 48 -- 285 3 2.2 NC NC -- NC 3 2.3 NC 3566 5 5.5 91 29 -- 212 1 2.6 NC NC -- NC 4 2.9 NC 3567 7 5.4 130 52 -- 268 3 2.4 NC NC -- NC 4 3.0 NC City Total 33 ...

Census Tract Obs Exp SIR Obs Exp SIR Obs Exp SIR 3561 1 2.1 NC NC -- NC 1 1.0 NC NC -- NC 0 1.2 NC NC 3562 2 3.8 NC NC -- NC 1 1.5 NC NC -- NC 1 2.2 NC NC 3563 5 3.5 144 46 -- 336 1 1.6 NC NC -- NC 4 1.9 NC NC 3564 9 5.2 172 79 -- 327 4 2.5 NC NC -- NC 5 2.7 185 60 3565 5 4.6 110 35 -- 256 2 2.1 NC NC -- NC 3 2.4 NC NC 3566 4 5.7 NC NC -- NC 1 2.6 NC NC -- NC 3 3.1 NC NC 3567 7 5.3 133 53 -- 273 3 2.2 NC NC -- NC 4 3.0 ...

TimePeriod Obs Exp SIR Obs Exp SIR Obs Exp SIR 1982 - 1988 33 30.1 110 75 -- 154 13 13.5 96 51 -- 164 20 16.6 121 1989 - 1995 33 29.6 111 77 -- 156 15 14.1 107 60 -- 176 18 15.6 116 1996 - 2001 26 20.0 130 85 -- 190 12 10.4 116 60 -- 202 14 9.6 145 Note: SIRs are calculated based on the exact number of expected cases. Expected number of cases presented are rounded to the nearest tenth. SIRs and 95% CI are not calculated when observed number of cases < 5. Obs = Observed number of cases 95% CI = 95% Confidence Interval Exp = Expected number of cases NC = Not calculated SIR = Standardized Incidence Ratio * = Statistical significance Data Source: Massachusetts ...

A221( ? )- Brain cancer tissues (formalin fixed) For research use only Specifications: • No. of cases: 30 • Tissue type: Brain cancer tissues • No. of spots: 2 spots from each cancer case (60 spots) 4 non-neoplastic spots (4 spots) •Total spots: 64 • Corresponding normal tissues with cancers: Yes • Diameter: 1. 5 mm Documents : • Product specification: layout, summary of tissue spots • H&E stained images • Detailed pathological information Layout: 1 2 3 4 5 6 7 8 9 10 A B C D E F G WHO and St.Anne/Mato grading system WHO designation St.Anne/Mayo designation : I Pilocytic astrocytoma : II Diffuse astrocytoma Astrocytoma grade 2 : III Anaplastic astrocytoma Astrocytoma ...